Journal of Gastroenterology and Hepatology最新文献

{"title":"Prevalence of small intestinal bacterial overgrowth in intestinal failure syndrome: A systematic review and meta-analysis.","authors":"Ayesha Shah, Thomas Fairlie, Mark Morrison, Neal Martin, Karin Hammer, Johann Hammer, Natasha Koloski, Ali Rezaie, Mark Pimentel, Purna Kashyap, Michael P Jones, Gerald Holtmann","doi":"10.1111/jgh.16668","DOIUrl":"https://doi.org/10.1111/jgh.16668","url":null,"abstract":"<p><strong>Background and aim: </strong>Patients with intestinal failure (IF) have abnormal intestinal anatomy, secretion, and dysmotility, which impairs intestinal homeostatic mechanisms and may lead to small intestinal bacterial overgrowth (SIBO). We conducted a systematic review and meta-analysis to determine the prevalence of SIBO in patients with IF and to identify risk factors for SIBO.</p><p><strong>Methods: </strong>MEDLINE (PubMed) and Embase electronic databases were searched from inception to December 2023 for studies that reported the prevalence of SIBO in IF. The prevalence rates, odds ratio (OR), and 95% confidence intervals of SIBO in IF and the risk factors for SIBO in IF were calculated using random effects model.</p><p><strong>Results: </strong>Final dataset included nine studies reporting on 407 patients with IF. The prevalence of SIBO in IF was 57.5% (95% CI 44.6-69.4), with substantial heterogeneity in this analysis (I² = 80.9, P = 0.0001). SIBO prevalence was sixfold higher in patients with IF who received parenteral nutrition (PN) compared with IF patients not on PN (OR = 6.0, 95% CI 3.0-11.9, P = 0.0001). Overall, the prevalence of SIBO in patients with IF using PPI/acid-suppressing agents (72.0%, 95% CI 57.5-83.8) was numerically higher compared with IF patients not using these agents (47.6%, 95% CI 25.7-70.2).</p><p><strong>Conclusions: </strong>This systematic review and meta-analysis suggests that there is an increased risk of SIBO in patients with IF and that PN, and potentially, the use of PPI/acid-suppressing agents is risk factors for SIBO development in patients with IF. However, the quality of evidence is low and can be attributed to lack of case-control studies and clinical heterogeneity seen in the studies.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of high-quality artificial intelligence for computer-aided diagnosis in determining subtypes of colorectal cancer.","authors":"Weihao Weng, Naohisa Yoshida, Yukiko Morinaga, Satoshi Sugino, Yuri Tomita, Reo Kobayashi, Ken Inoue, Ryohei Hirose, Osamu Dohi, Yoshito Itoh, Xin Zhu","doi":"10.1111/jgh.16661","DOIUrl":"https://doi.org/10.1111/jgh.16661","url":null,"abstract":"<p><strong>Background and aim: </strong>There are no previous studies in which computer-aided diagnosis (CAD) diagnosed colorectal cancer (CRC) subtypes correctly. In this study, we developed an original CAD for the diagnosis of CRC subtypes.</p><p><strong>Methods: </strong>Pretraining for the CAD based on ResNet was performed using ImageNet and five open histopathological pretraining image datasets (HiPreD) containing 3 million images. In addition, sparse attention was introduced to improve the CAD compared to other attention networks. One thousand and seventy-two histopathological images from 29 early CRC cases at Kyoto Prefectural University of Medicine from 2019 to 2022 were collected (857 images for training and validation, 215 images for test). All images were annotated by a qualified histopathologist for segmentation of normal mucosa, adenoma, pure well-differentiated adenocarcinoma (PWDA), and moderately/poorly differentiated adenocarcinoma (MPDA). Diagnostic ability including dice sufficient coefficient (DSC) and diagnostic accuracy were evaluated.</p><p><strong>Results: </strong>Our original CAD, named Colon-seg, with the pretraining of both HiPreD and ImageNET showed a better DSC (88.4%) compared to CAD without both pretraining (76.8%). Regarding the attentional mechanism, Colon-seg with sparse attention showed a better DSC (88.4%) compared to other attentional mechanisms (dual: 79.7%, ECA: 80.7%, shuffle: 84.7%, SK: 86.9%). In addition, the DSC of Colon-seg (88.4%) was better than other types of CADs (TransUNet: 84.7%, MultiResUnet: 86.1%, Unet++: 86.7%). The diagnostic accuracy of Colon-seg for each histopathological type was 94.3% for adenoma, 91.8% for PWDA, and 92.8% for MPDA.</p><p><strong>Conclusion: </strong>A deep learning-based CAD for CRC subtype differentiation was developed with pretraining and fine-tuning of abundant histopathological images.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2.","authors":"Jiemin Cheng, Siqi Yang, Diwen Shou, Jiawei Chen, Yongqiang Li, Chen Huang, Huiting Chen, Yongjian Zhou","doi":"10.1111/jgh.16662","DOIUrl":"https://doi.org/10.1111/jgh.16662","url":null,"abstract":"<p><strong>Background and aim: </strong>Lipid metabolism disorder is the primary feature of numerous refractory chronic diseases. Fatty acid oxidation, an essential aerobic biological process, is closely related to the progression of NAFLD. The forkhead transcription factor FOXO1 has been reported to play an important role in lipid metabolism. However, the molecular mechanism through which FOXO1 regulates fatty acid oxidation remains unclear.</p><p><strong>Methods: </strong>Transcriptomic analysis was performed to examine the cellular expression profile to determine the functional role of FOXO1 in HepG2 cells with palmitic acid (PA)-induced lipid accumulation. FOXO1-binding motifs at the promoter region of aldehyde dehydrogenase 1 family member L2 (ALDH1L2) were predicted via bioinformatic analysis and confirmed via luciferase reporter assay. Overexpression of ALDH1L2 was induced to recover the impaired fatty acid oxidation in FOXO1-knockout cells.</p><p><strong>Results: </strong>Knockout of FOXO1 aggravated lipid deposition in hepatic cells. Transcriptomic profiling revealed that knockout of FOXO1 increased the expression of genes associated with fatty acid synthesis but decreased the expression of carnitine palmitoyltransferase1a (CPT1α) and adipose triglyceride lipase (ATGL), which contribute to fatty acid oxidation. Mechanistically, FOXO1 was identified as a transcription factor of ALDH1L2. Knockout of FOXO1 significantly decreased the protein expression of ALDH1L2 and CPT1α in vitro and in vivo. Furthermore, overexpression of ALDH1L2 restored fatty acid oxidation in FOXO1-knockout cells.</p><p><strong>Conclusion: </strong>The findings of this study indicate that FOXO1 modulates fatty acid oxidation by targeting ALDH1L2.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","authors":"Wasit Wongtrakul, Sorachat Niltwat, Natthinee Charatcharoenwitthaya, Khemajira Karaketklang, Phunchai Charatcharoenwitthaya","doi":"10.1111/jgh.16666","DOIUrl":"https://doi.org/10.1111/jgh.16666","url":null,"abstract":"<p><strong>Background and aim: </strong>Patients with type 2 diabetes mellitus (T2DM) face a heightened susceptibility to advanced fibrosis, a condition linked to adverse clinical outcomes. However, reported data on liver fibrosis severity among individuals with T2DM vary significantly across studies with diverse characteristics. This meta-analysis aimed to estimate the global prevalence of advanced fibrosis among T2DM patients.</p><p><strong>Methods: </strong>A comprehensive systematic search of the EMBASE and MEDLINE databases from inception to November 2022 was conducted to identify studies assessing advanced fibrosis in individuals with T2DM. Random-effects models were utilized to calculate point estimates of prevalence, accompanied by 95% confidence interval (CI). Meta-regression with subgroup analysis was employed to address heterogeneity.</p><p><strong>Results: </strong>We identified 113 eligible studies involving 244,858 individuals from 29 countries. Globally, the prevalence of advanced fibrosis among T2DM patients was 19.5% (95% CI 16.8-22.4%). Regionally, the prevalence rates were as follows: 60.5% in West Asia (95% CI 50.3-70.4%), 24.4% in South Asia (95% CI 16.2-33.7%), 20.1% in East Asia (95% CI 14.7-26.1%), 20.0% in Europe (95% CI 15.8-24.6%), 15.8% in North America (95% CI 11.0-21.3%), and 11.3% in South America (95% CI 6.2-17.5%). The prevalence of advanced fibrosis varied notably based on the study setting and diagnostic methodology employed. Meta-regression models highlighted that 45.13% of the observed heterogeneity could be attributed to combined diagnostic modality and study setting.</p><p><strong>Conclusions: </strong>Globally, approximately one fifth of the T2DM population presents advanced fibrosis, with prevalence differing across geographical regions. Our findings underscore the need for effective strategies to alleviate its global burden.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature.","authors":"Odysseas P Chatzipanagiotou, Constantinos Loukas, Michail Vailas, Nikolaos Machairas, Stylianos Kykalos, Georgios Charalampopoulos, Dimitrios Filippiadis, Evangellos Felekouras, Dimitrios Schizas","doi":"10.1111/jgh.16663","DOIUrl":"https://doi.org/10.1111/jgh.16663","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatocellular carcinoma (HCC) diagnosis mainly relies on its pathognomonic radiological profile, obviating the need for biopsy. The project of incorporating artificial intelligence (AI) techniques in HCC aims to improve the performance of image recognition. Herein, we thoroughly analyze and evaluate proposed AI models in the field of HCC diagnosis.</p><p><strong>Methods: </strong>A comprehensive review of the literature was performed utilizing MEDLINE/PubMed and Web of Science databases with the end of search date being the 30th of September 2023. The MESH terms \"Artificial Intelligence,\" \"Liver Cancer,\" \"Hepatocellular Carcinoma,\" \"Machine Learning,\" and \"Deep Learning\" were searched in the title and/or abstract. All references of the obtained articles were also evaluated for any additional information.</p><p><strong>Results: </strong>Our search resulted in 183 studies meeting our inclusion criteria. Across all diagnostic modalities, reported area under the curve (AUC) of most developed models surpassed 0.900. A B-mode US and a contrast-enhanced US model achieved AUCs of 0.947 and 0.957, respectively. Regarding the more challenging task of HCC diagnosis, a 2021 deep learning model, trained with CT scans, classified hepatic malignant lesions with an AUC of 0.986. Finally, a MRI machine learning model developed in 2021 displayed an AUC of 0.975 when differentiating small HCCs from benign lesions, while another MRI-based model achieved HCC diagnosis with an AUC of 0.970.</p><p><strong>Conclusions: </strong>AI tools may lead to significant improvement in diagnostic management of HCC. Many models fared better or comparable to experienced radiologists while proving capable of elevating radiologists' accuracy, demonstrating promising results for AI implementation in HCC-related diagnostic tasks.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Helicobacter pylori infection, osteoporosis, and fracture","authors":"Jing Tong Tan, Ching Lung Cheung, Ka Shing Cheung","doi":"10.1111/jgh.16664","DOIUrl":"https://doi.org/10.1111/jgh.16664","url":null,"abstract":"Osteoporotic fracture is a prevalent noncommunicable disease globally, causing significant mortality, morbidity, and disability. As the population ages, the healthcare and economic burden of osteoporotic fracture is expected to increase further. Due to its multifactorial features, the development of osteoporotic fracture involves a complex interplay of multiple risk factors, including genetic, environmental, and lifestyle factors. <jats:styled-content style=\"fixed-case\"><jats:italic>Helicobacter pylori</jats:italic></jats:styled-content>, which infects approximately 43% of the world's population, has been associated with increased fracture risk due to hypochlorhydria from atrophic gastritis and systemic inflammation from elevated pro‐inflammatory cytokines. However, the potential impact of <jats:styled-content style=\"fixed-case\"><jats:italic>H. pylori</jats:italic></jats:styled-content> infection and eradication on fracture risk remains contentious among various studies due to the study design and inadequate adjustment of confounding factors including baseline gastritis phenotype. In this review, we provided a comprehensive evaluation of the current evidence focusing on the underlying mechanisms and clinical evidence of the association between <jats:styled-content style=\"fixed-case\"><jats:italic>H. pylori</jats:italic></jats:styled-content> infection and osteoporotic fracture. We also discussed the potential benefits of <jats:styled-content style=\"fixed-case\"><jats:italic>H. pylori</jats:italic></jats:styled-content> eradication on fracture risk.","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141513843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load","authors":"Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai","doi":"10.1111/jgh.16667","DOIUrl":"https://doi.org/10.1111/jgh.16667","url":null,"abstract":"Background and AimAmong low viral load (DNA of hepatitis B virus (HBV) was &lt; 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive.MethodsThe retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e‐antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow‐up. CHB patients with low‐viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed.ResultsA total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow‐up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow‐up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years <jats:italic>vs</jats:italic> 65.5 years; <jats:italic>P</jats:italic> = 0.01), had lower HBV DNA levels (1.3 log<jats:sub>10</jats:sub> IU/mL <jats:italic>vs</jats:italic> 2.3 log<jats:sub>10</jats:sub> IU/mL; <jats:italic>P</jats:italic> = 0.003), and higher proportion of prior NAs‐treated history. Logistic regression analysis revealed that the factors associated with factors associated with HBsAg loss were age &lt; 60 years (OR/CI: 3.95/1.15–13.60, <jats:italic>P</jats:italic> = 0.03), prior NAs‐treated history (OR/CI: 7.59/1.42–40.51, <jats:italic>P</jats:italic> = 0.01) and current NAs‐treated (OR/CI: 0.19/0.05–0.71, <jats:italic>P</jats:italic> = 0.01).ConclusionsIn the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141513842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Single colonoscopy-based colorectal cancer screening as a real-world cost-effective option","authors":"Tiing Leong Ang MBBS, FRCP Edn, FAMS, FASGE, FJGES","doi":"10.1111/jgh.16671","DOIUrl":"10.1111/jgh.16671","url":null,"abstract":"<p>Globally, colorectal cancer (CRC) ranks third in terms of incidence but second in terms of mortality.<span>¹</span> CRC screening is recommended by guidelines as it has been shown to reduce CRC incidence<span>²</span> and CRC-related mortality.<span>^{2, 3}</span> The fecal immunochemical test (FIT) and colonoscopy are both widely used for CRC screening. A systematic review and meta-analysis of six randomized controlled trials and 17 cost-effectiveness studies reported that although FIT had a detection rate of CRC comparable with colonoscopy, it had lower detection rates of any adenoma and advanced adenoma. Nonetheless, annual or biennial FIT appeared to be very cost-effective compared with colonoscopy every 10 years.<span>⁴</span> However, in the real-world setting, the uptake of serial CRC screening tests remains low. A single time point screening test, although less ideal, may be more realistic. Hence, to clarify whether a single colonoscopy-based screening or a single FIT-based screening is superior is of practical relevance in the real-world setting. Currently, there is a paucity of such cost-effectiveness data.</p><p>In this issue of <i>Journal of Gastroenterology and Hepatology</i>, Ishibashi <i>et al</i>. conducted a cost-effectiveness analysis of single colonoscopy versus single FIT for CRC diagnosis and treatment.<span>⁵</span> A microsimulation model was constructed based on real-world observational data that compared single colonoscopy-based screening with single FIT-based screening. The total costs of diagnosis and treatment of the detected lesions using the two strategies were calculated and the incremental cost-effectiveness ratio per life year gained assessed. It was concluded that the single colonoscopy-based strategy was more cost-effective than FIT, especially for patients aged 60–69 years, and when the adenoma detection rate (ADR) during colonoscopy exceeded 30% or the positive FIT rate was lower than 8.6% in the FIT-based strategy. This study is important and of practical relevance as it provides data demonstrating that in the context of performing only a one-time screening test, in the relevant context, a single colonoscopy may be more cost-effective than FIT-based test. A detailed costing information for both diagnosis and treatment was provided. Although the FIT test itself is cheaper, when consideration of the earlier disease states of detected colonic neoplasia and differences in treatment costs are taken into account, a single colonoscopy-based strategy could actually be more cost-effective. Another strength of the study is that it established a threshold of parameters for the colonoscopy to be effective. The main limitation to this study would be its generalizability. Costs of tests and treatment do differ between countries, and likewise, there may be differences in ADR and FIT-positive rates between different patient populations.</p><p>Cost-effectiveness analyses ","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141513845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of same-day preparation with sodium picosulfate plus magnesium citrate on the day of colonoscopy for bowel preparation: Multicenter, single-arm, open-label study.","authors":"Hitomi Hori, Nobuaki Ikezawa, Shinwa Tanaka, Chise Ueda, Mizuho Fujisawa, Shinya Hoki, Hiroshi Tanabe, Ryosuke Ishida, Norihiro Okamoto, Hiroshi Takayama, Haruka Miyazaki, Hiroya Sakaguchi, Masato Kinoshita, Hirofumi Abe, Tetsuya Yoshizaki, Makoto Ooi, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama","doi":"10.1111/jgh.16660","DOIUrl":"10.1111/jgh.16660","url":null,"abstract":"<p><strong>Background and aim: </strong>Sodium picosulfate plus magnesium citrate (SP + MC) is a well-tolerated bowel preparation agent. However, Japan currently approves only two methods of taking SP + MC: the day-before and split-dose preparation, without approval of same-day preparations. This study aimed to evaluate the efficacy and safety of same-day SP + MC preparations.</p><p><strong>Methods: </strong>This was a multicenter, single-arm, nonrandomized, open-label study. We enrolled 145 Japanese patients between June and December 2023. The patients received two sachets of SP + MC dissolved in 300 ml of water and 1200 mL or more of clear liquid on the day of colonoscopy. Bowel cleansing efficacy, adverse events (AEs), and patient satisfaction were evaluated.</p><p><strong>Results: </strong>Of the enrolled patients, 137 underwent colonoscopy according to our protocol. Bowel preparation was adequate in 133 patients (97.1%). The mean total Boston Bowel Preparation Score was 8.3 ± 1.2. Five patients experienced AEs (3.6%): two (1.5%), abdominal pain; one (0.73%), ischemic enteritis; one (0.73%), vomiting or nausea; and one (0.73%), headache. All AEs were treated conservatively. None of the patients exhibited abnormal blood test results or clinical symptoms after receiving SP + MC. Regarding patient satisfaction, all patients were able to take SP + MC as directed; 136 (99.2%) expressed a preference for this bowel preparation for future colonoscopies.</p><p><strong>Conclusion: </strong>The same-day SP + MC preparation showed high bowel-cleansing efficacy and satisfaction in Japanese patients without serious AEs.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma.","authors":"Soe Thiha Maung, Natthaporn Tanpowpong, Minchanat Satja, Sombat Treeprasertsuk, Roongruedee Chaiteerakij","doi":"10.1111/jgh.16643","DOIUrl":"10.1111/jgh.16643","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) constitutes the majority of liver cancers and significantly impacts global cancer mortality. While ultrasound (US) with or without alpha-fetoprotein is the mainstay for HCC surveillance, its limitations highlight the necessity for more effective surveillance tools. Therefore, this review explores evolving imaging modalities and abbreviated magnetic resonance imaging (MRI) (AMRI) protocols as promising alternatives, addressing challenges in HCC surveillance.</p><p><strong>Areas covered: </strong>This comprehensive review delves into the evaluation and challenges of HCC surveillance tools, focusing on non-contrast abbreviated MRI (NC-AMRI) and contrast-enhanced abbreviated MRI protocols. It covers the implementation of AMRI for HCC surveillance, patient preferences, adherence, and strategies for optimizing cost-effectiveness. Additionally, the article provides insights into prospects for HCC surveillance by summarizing meta-analyses, prospective studies, and ongoing clinical trials evaluating AMRI protocols.</p><p><strong>Expert opinion: </strong>The opinions underscore the transformative impact of AMRI on HCC surveillance, especially in overcoming US limitations. Promising results from NC-AMRI protocols indicate its potential for high-risk patient surveillance, though prospective studies in true surveillance settings are essential for validation. Future research should prioritize risk-stratified AMRI protocols and address cost-effectiveness for broader clinical implementation, alongside comparative analyses with US for optimal surveillance strategies.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}